NasdaqCM:AXGNMedical Equipment
Is Axogen (AXGN) Quietly Redefining Nerve Repair Moats With Avance and New Portfolio Backing?
TimesSquare Capital Management recently added Axogen, Inc. to its U.S. Small Cap Growth Strategy, following the company’s report of US$59.9 million in fourth-quarter 2025 revenue and 21.3% year-over-year growth from its peripheral nerve repair portfolio.
A key element of the story is Axogen’s Avance Nerve Graft, currently the only FDA-approved implantable biological nerve allograft, which underscores its differentiated position in peripheral nerve regeneration.
We’ll now examine how Axogen’s...